Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
SASana Biotechnology, Inc. logo

Sana Biotechnology, Inc. (SANA)

NASDAQ Global Select · Currency in USD
$2.33 ▼ -0.04 (-1.69%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.35 ▲ +0.02 (+0.86%)
After hours: Oct 23, 7:33 PM ET

Summary

Previous Close
$2.37
Open
$2.35
Day's Range
$2.25 – $2.38
52 Week Range
$2.22 – $5.70
Volume
1,707,921
Avg. Volume
3,271,177
Market Cap
$697.51M
Beta (5Y Monthly)
2.19
PE Ratio (TTM)
--
EPS (TTM)
-$0.72
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$8.50

Profile: Sana Biotechnology, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
142
CEO
Steven D. Harr
Website
sana.com

Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.15
DateEst.Actual
Aug 11, 2026-$0.15-$0.22Miss
May 11, 2026-$0.15-$0.14Beat
Mar 3, 2026-$0.13-$0.16Miss
Nov 6, 2025-$0.18-$0.15Beat
Aug 11, 2025-$0.20-$0.39Miss
May 8, 2025-$0.22-$0.20Beat

Analyst view

Consensus price target
$8.50 ▲ +264.8%
Range $7.00 – $12.00
Rating: Buy
Buy 82% · Hold 18% · Sell -0%

Get free alerts on SANA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.